<DOC>
	<DOCNO>NCT02709343</DOCNO>
	<brief_summary>This study design lung transplant patient develop chronic lung allograft dysfunction ( CLAD ) . Consented patient receive 4 intravenous dos allogeneic , bone-marrow-derived MSCs ( 2*10^6 cells/kg/dose ) match placebo period 2 week 12 month follow .</brief_summary>
	<brief_title>Trial Bone-marrow Derived Mesenchymal Stromal Cells ( MSC ) New Onset Chronic Lung Allograft Dysfunction</brief_title>
	<detailed_description>This phase 2 , multi-center , randomize study ( n=82 , 1:1 MSC : placebo ) consent patient receive 4 intravenous dos IMP period 2 week . Patients must provide write informed consent meet Inclusion Criteria none Exclusion Criteria eligible . Screening procedure include obtain medical history , current medication , questionnaire , vital sign , Chest Xray , 6 Minute walk test blood test . Historical chest CT full lung function 12 week prior screen may use . Bronchoscopy biopsy must perform 6 month prior screen . A bronchoscopy bronchoalveolar lavage ( BAL ) require , however need repeat perform within 14 day prior baseline visit . Patients receive 4 infusion MSC/placebo period 2 week , follow Week 3,6,10,14,28,41 week 54 .</detailed_description>
	<criteria>1 . Bilateral lung transplant recipient age â‰¥ 18 year least 6 month posttransplant . Patients organ transplant ( eg heart , liver , kidney ) undergone lobar transplantation , retransplantation , potentially eligible . 2 . Newonset CLAD ( define persistent ( 3weeks apart ) fall FEV1 least 20 % mean two best posttransplant value take least 3 week apart ) 6 month prior screen visit . Other cause fall FEV1 ( acute cellular humoral rejection , active infection , anastomotic stenosis etc . ) must exclude per international guideline . 3 . Stable immunosuppression regimen , assess investigator , 8 week prior screen visit . 4 . Absence significant , untreated , gastrooesophageal reflux disease ( GORD ) assess Investigator . 5 . Available specified assessment study site completion study , include protocol bronchoscopies . 6 . Provision write informed consent . 1 . Any condition opinion Investigator may interfere safety patient , / completion require followup visit evaluation study objectives 2 . Untreated cellular humoral rejection 3 . Clinically meaningful untreated viral , bacterial fungal infection 4 . Use azithromycin another macrolide antibiotic , commence within 8 week screen visit 5 . Intravenous pulse methylprednisolone , within 8 week screen visit 6 . Use extracorporeal photopheresis , within 8 week screen visit 7 . Use total lymphoid irradiation , within 8 week screen visit 8 . Fundoplication , within 8 week screen visit 9 . Poor functional status expect survive 6 month 10 . Allergy beef product 11 . Women pregnant , breastfeed unwilling use adequate contraception 12 . Patients currently participate another interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>